# Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs

> **NCT02350764** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 29 (actual)

## Conditions studied

- Advanced Stage Non-small Cell Lung Cancer

## Interventions

- **DRUG:** nivolumab
- **DRUG:** pilimumab

## Key facts

- **NCT ID:** NCT02350764
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-20
- **Primary completion:** 2023-09-25
- **Final completion:** 2023-09-25
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-05-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02350764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02350764, "Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02350764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*